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INTRODUCTION l-Deprenyl (selegiline, (R)-(-)-deprenyl), a selective inhibitor of monoamine-oxidase, type-B enzyme (MAO-B), is best known for its proven clinical efficacy in the treatment of Parkinson's disease (PD), but it has been clinically evaluated for treatment of Alzheimer's disease (Sano et al., 1997; Tariot et al., 1998) and as a transdermal patch for treatment of major depressive disorders (Amsterdam, 2003) . (R)-(-)-deprenyl has also been proposed as a cognitive enhancer (Gelowitz et al., 1994) , as a treatment for attention deficit hyperactivity disorder (Akhondzadeh et al., 2003) , as a treatment for drug dependence (Houtsmuller et al., 2004) (Grasing and Ghosh, 1998) and as an aid for smoking cessation (George et al., 2003) .
Blockade of MAO-B enzyme activity by MAO-B selective doses of (R)-(-)-deprenyl (0.5 to 4.0 mg/kg, i.p., in rats; Paterson et al., 1991) can alter circulating and brain levels of catecholamines like dopamine and norepinephrine, and of their metabolites (Okuda et al., 1992) , potentiate neuronal responses to dopamine agonists (Paterson et al., 1991) and reduce the formation of highly reactive oxygen species (Ebadi et al., 2002; which may lead to cell damage and/or cell death. These actions might contribute to (R)-(-)-deprenyl's beneficial therapeutic effects. (R)-(-)-deprenyl treatment alone, in the absence of l-DOPA treatment, slows the progression of PD indicating neuroprotective effects in humans (see Magyar and Haberle, 1999 , for review). These effects are consistent with numerous studies demonstrating neuroprotective effects of (R)-(-)-deprenyl in in-vitro models of neurotoxicity in cell lines (Ebadi et al., 2002; , which do not appear to be related to its ability to bind to and inactivate the MAO-B enzyme (Magyar and Haberle, 1999; Ebadi et al., 2002) . Among the many psychoactive substances thought to play a role in the effects of (R)-(-)-deprenyl, the most important are ß-phenylethylamine (ß-PEA), brain levels of which increase dramatically after (R)-(-)-deprenyl treatment because of MAO-B blockade (Paterson et al., 1991; Paterson et al., 1995) , and (R)-(-)-methamphetamine and (R)-(-)-amphetamine, which are two of the main metabolites of (R)-(-)-deprenyl (Heinonen et al., 1994; Lajtha et al., 1996) .
(R)-(-)-
Methamphetamine, (R)-(-)-amphetamine, and ß-PEA have distinct pharmacological properties, including potentially undesirable effects, such as the ability to reinforce drug-seeking behavior in animal models of drug abuse (Yokel and Pickens, 1973; Shannon and Degregorio, 1982; Winger et al., 1994; Sannerud et al., 1996; Bergman et al., 2001 ).
However, (R)-(-)-deprenyl has not been reported to induce any drug-dependence syndrome related to its non-medical, recreational, use or abuse. Nonetheless, the increased levels of psychostimulant-like substances produced after its administration has been viewed as potentially harmful, and the abuse liability of (R)-(-)-deprenyl has been a matter of debate (Yasar et al., 1996; Wu and Zhu, 1999; Yasar et al., 2005a) .
Although (R)-(-)-deprenyl is not self-administered above vehicle placebo levels by monkeys (Winger et al., 1994; Yasar et al., 2005b ) under fixed-ratio or second-order schedules of intravenous drug injection, it can potentiate the reinforcing effects of intravenously administered ß-PEA (Bergman et al., 2001 ) and can induce conditioned place preferences in rats (Wu and Zhu, 1999) . In addition, at high non-therapeutic doses, (R)-(-)-deprenyl can substitute for (S)-(+)-amphetamine, (S)-(+)-methamphetamine and cocaine in rats and monkeys when studied using drug-discrimination procedures (Yasar et al., 1993; Yasar and Bergman, 1994; This article has not been copyedited and formatted. The final version may differ from this version. We first compared the discriminative-stimulus effects of (R)-(-)-deprenyl with those of Ro 16-6491, a selective and reversible inhibitor of MAO-B enzyme activity without psychoactive metabolites (Da Prada et al., 1987) . Stimulus-shock termination and food-presentation schedules were used in rats trained to discriminate (S)-(+)-methamphetamine or cocaine from a saline placebo in order to allow direct comparisons with previous studies. The metabolic enzyme inhibitor SKF 525A was then tested in combination with (R)-(-)-deprenyl, to determine whether blockade of the CYP-450 enzyme, which converts (R)-(-)-deprenyl to (R)-(-)-methamphetamine and (R)-(-)-amphetamine metabolites (Yoshida et al., 1987) , reduces the ability of (R)-(-)-deprenyl to produce (S)-(+)-methamphetamine -or cocaine-like discriminative effects. In addition, (R)-(-)-deprenyl was tested in combination with NSD 1015, a dopamine-decarboxylase enzyme inhibitor (Carlsson et al., 1972) , to determine whether blockade of the accumulation of ß-PEA, a substrate for the MAO-B enzyme produced by decarboxylation of the amino acid lphenylalanine, reduced the ability of (R)-(-)-deprenyl to produce psychostimulant-like discriminative-stimulus effects.
This article has not been copyedited and formatted. The final version may differ from this version. weighing 275 to 325 g at the start of the experiments, were trained under a stimulus-shock termination schedule. Between experimental sessions, rats were housed in groups of three per cage with free access to water and food. Sixteen additional male Fisher F344 rats, weighing around 350 g at the start of the experiments, were trained under a food-presentation schedule and were housed individually with free access to water. These rats had food availability restricted such that their weights were maintained at approximately 80% of initial free-feeding weights throughout the experiments. All rats were housed in a temperature-and humidity-controlled room that was illuminated from 6:00 a.m. to 6:00 p.m. and experiments were conducted during the light phase. The rats were experimentally naive at the start of this study. 
Discrimination performance with (S)-(+)-methamphetamine as the training drug.
Both stimulus-shock termination and food-presentation schedules were used in order to allow direct comparisons with previous studies (Yasar et al., 1993; . The food-presentation baseline provided a measure of behaviorally active disruptive effects that can appear as dose of test drugs are increased, while the stimulus-shock termination baseline allowed testing of higher doses of drugs, which might otherwise eliminate behavior and preclude measurement of discriminative effects. Rats were trained under a 5-response fixed-ratio (FR5) schedule of stimulus-shock termination or under a 10-response fixed-ratio (FR10) schedule of food-pellet delivery to respond on one lever after an injection of a training dose of 1.0 mg/kg of (S)-(+)-methamphetamine and on the other lever after either an injection of 1.0 mg/ml of saline vehicle or no injection (frequent no-injection conditions were interspersed with infrequent saline injections to minimize frequency of injection during training). Injections of methamphetamine or saline were given i.p. 15 min before the start of the session. Under the schedule of stimulusshock termination, a white house light was turned on at the start of the session; in the presence of on the lever appropriate to the pre-session treatment terminated the white house light and shock presentations and initiated a 45-sec timeout during which lever-pressing responses had no specified consequences and a dim red light was present. Under the schedule of food presentation, the completion of 10 consecutive responses on the lever appropriate to the pre-session treatment produced delivery of a 45-mg food pellet and initiated a 45-sec timeout during which leverpressing responses had no specified consequences and the chamber was dark. Under both the stimulus-shock termination and the food-presentation procedures, responses on the incorrect lever had no programmed consequences other than to reset the response requirement to 5 or 10 on the correct lever. After each timeout the next trial began. Each session ended after completion of 20 trials or after 30 min, whichever occurred first. Mello and Stolerman, 1977; Colpaert et al., 1979) , we previously found that high doses of (R)-(-)-deprenyl produced complete generalization to a (S)-(+)-amphetamine training stimulus but not to a cocaine training stimulus under stimulus-shock termination schedules (Yasar et al., 1993; . Consequently, an additional group of rats was trained under a FR5 schedule of stimulus-shock termination to respond on one lever after an injection of a training dose of 10 mg/kg of cocaine and on the other lever after an injection of 1.0 mg/ml of saline vehicle.
Training conditions were identical to those described above for ( (Berry et al., 1994; . Each drug dose or combination was usually tested twice. On some no-drug sessions the saline injection was omitted; although results were similar to sessions when saline was injected, only those no-drug sessions with saline injections were used for data analysis. All drug doses and calculations are based on the salts. Over the range of doses studied, none of the drugs significantly affected rates of lever-press responding under the food-presentation schedule (Figure 2, bottom panel) , with the exception of the high 3.0 mg/kg dose of (S)-(+)-methamphetamine that markedly depressed food-reinforced responding (F(3,21)=11.82, p < 0.001) and a 100 mg/kg dose of Ro 16-6491 that completely suppressed food-maintained responding (F(5,35)=8.46, p < 0.001). (Table 1) . Over the range of doses studied, none of these drugs or drug combinations significantly affected rates of lever-press responding under the stimulus-shock termination schedule with (S)-(+)-methamphetamine as the training stimulus ( Figures 3A, and 4A , bottom panels).
Drug-discrimination studies in (S)-(+)-methamphetamine-trained rats under the stimulusshock termination schedule.

Increasing doses of (S)-(+)-methamphetamine produced dose-dependent increases in drug-
Drug-discrimination studies in cocaine-trained rats under the stimulus-shock termination schedule.
Increasing doses of cocaine produced dose-dependent increases in drug-lever responding with complete generalization to the cocaine-training stimulus occurring at the 10.0-mg/kg training dose of cocaine ( Figure 3B (Table 1) .
Over the range of doses studied, none of the drugs significantly affected rates of lever-press responding under the stimulus-shock termination schedule with cocaine as the training stimulus ( Figures 3B and 4B, bottom panels) . Since (R)-(-)-deprenyl is a selective blocker of the MAO-B enzyme, endogenous substrates of this enzyme, such as ß-PEA, might accumulate after MAO-B blockade to produce neurobiological effects (Paterson et al., 1991; Paterson et al., 1995) , which are discriminated by rats as similar to those of psychostimulant drugs. However, Ro 16-6491 (Da Prada et al., 1987) , a drug that shares with (R)-(-)-deprenyl the ability to selectively block MAO-B enzyme activity but does not share with (R)-(-)-deprenyl the metabolic conversion to methamphetamine and amphetamine metabolites, did not produce any significant generalization to (S)-(+)-methamphetamine or cocaine training stimuli. Ro 16-6491 is roughly equipotent to, or two-fold more potent than, (R)-(-)-deprenyl in its ability to bind to and inactivate the MAO-B enzyme, depending on the assay used (Cesura et al., 1988) . Also, the range of i. (Colpaert et al., 1979; Glennon et al., 1984; Yasar et al., 1993; Bondareva et al., 2002) and monkeys (Yasar and Bergman, 1994) and to be actively selfadministered by rats (Yokel and Pickens, 1973) and monkeys (Winger et al., 1994) . We (Yasar et al., 1993 . Similarly, Bondareva et al. (2002) found that a dose of 2.0 mg/kg (R)-(-)-methamphetamine produced complete generalization to a 1.0 mg/kg training dose of d(S)-(+)-methamphetamine. In contrast, 10 to 30 mg/kg doses of (R)-(-)-deprenyl were required to produce complete generalization to training doses of 1.0 mg/kg (S)-(+)-amphetamine or (R)-(-)-methamphetamine or 10.0 mg/kg cocaine in our present experiments and in our previous studies (Yasar et al., 1993; Thus, (R)-(-)-methamphetamine and (R)-(-)-amphetamine are about two-fold less potent than their respective (S)-(+)-stereoisomers, but they are equally effective in producing these discriminative-stimulus effects and are five-to fifteenfold more potent than (R)-(-)-deprenyl itself (Winger et al., 1994; Yasar and Bergman, 1994) .
Doses of (R)-(-)-methamphetamine and (R)-(-)-amphetamine which had psychostimulant-like
discriminative effects in previous studies (0.3 to 2.0 mg/kg; Colpaert et al., 1979; Glennon et al., 1984; Yasar et al., 1993; Bondareva et al., 2002) fall in the range of doses obtained by metabolic transformation of (R)-(-)-deprenyl after systemic administration. For example, Melega et al. (1999) showed that brain levels of metabolically generated (R)-(-)-amphetamine after a 10 mg/kg subcutaneous dose of (R)-(-)-deprenyl in rats corresponded to those that would be obtained after a 0.4 mg/kg dose of (R)-(-)-methamphetamine. Thus, levels of metabolically generated (R)-(-)-methamphetamine after a 30 mg/kg dose of (R)-(-)-deprenyl would correspond to levels after a 1.2 mg/kg dose of (R)-(-)-methamphetamine. Also, these estimates are somewhat undervalued, since they consider only metabolically generated (R)-(-)-methamphetamine, and not the smaller amounts of metabolically generated (R)-(-)-amphetamine that would be produced after administration of (R)-(-)-deprenyl. Finally, Melega et al. (1999) observed peak brain levels of (R)-(-)-methamphetamine 30 min after administration in rats, This article has not been copyedited and formatted. The final version may differ from this version. (Yoshida et al., 1987) . Administration of a 50 mg/kg dose of SKF 525A, which is fully effective in blocking the CYP450 enzyme responsible for the metabolism of (R)-(-)-deprenyl (Engberg et al., 1991; Haberle et al., 2002; , completely blocked, or significantly reduced, the ability of (R)-(-)-deprenyl to produce generalization to (S)-(+)-methamphetamine-and cocaine-training stimuli under both the food-reinforcement and stimulus-shock termination schedules. In previous experiments with rats (Engberg et al., 1991) , (R)-(-)-methamphetamine, in doses relevant to the formation of (R)-(-)-methamphetamine metabolites from (R)-(-)-deprenyl (Melega et al., 1999) , produced locomotor activation effects similar to those of (R)-(-)-deprenyl and the effects of (R)-(-)-deprenyl, but not those of (R)-(-)-methamphetamine, were blocked by pretreatment with 50 mg/kg of SKF 525A. The present results are consistent with these previous findings and show for the first time that when (R)-(-)-deprenyl metabolism is blocked, and there is no transformation of (R)-(-)-deprenyl into its amphetamine-like metabolic products, it looses its ability to produce psychostimulant-like discriminative effects. Thus, transformation to active metabolites appears to primarily mediate the psychostimulant-like discriminative effects of (R)-(-)-deprenyl in this study and in numerous previous studies. small amounts, and it is usually rapidly metabolized by the MAO-B enzyme after its synthesis from ß-phenyl-alanine. ß-PEA appears to play several neurobiological roles in drug reinforcement processes in the brain. It has been shown to inhibit the neuronal membrane transporter protein and to increase extracellular brain levels of dopamine, epinephrine and serotonin, with potencies comparable to that of amphetamines (Dyck, 1984; Sotnikova et al., 2004) . Moreover, ß-PEA has amphetamine-like, behavioral effects that include stimulation of locomotor activity and production of stereotyped movements (Timar and Knoll, 1986; Barroso and Rodriguez, 1996) and can maintain intravenous self-administration behavior in different animal species under some conditions (Shannon and Degregorio, 1982; Sannerud et al., 1996; Bergman et al., 2001) . Note that all of these biochemical, behavioral, and reinforcing effects of ß-PEA were obtained after exogenous administration of large amounts of the drug, which likely produced brain levels at least 100 fold higher than normal physiological levels. Although MAO-B inhibition may increase brain levels of ß-PEA to such high concentrations (Paterson et al., 1991; Paterson et al., 1995) , acute doses of MAO-B blockers such as (R)-(-)-deprenyl usually have limited effects and chronic dosing is usually necessary to produce near complete inhibition (Lamensdorf and Finberg, 1997) . However, acute blockade of MAO-B activity by (R)-(-)-deprenyl has been shown to potentiate locomotor and stereotypic effects (Timar and Knoll, 1986; Barroso and Rodriguez, 1996) , as well as reinforcing effects (Bergman et al., 2001) The drug NSD 1015 blocks the dopamine-decarboxylase enzyme that converts the amino-acid ß-phenylalanine into ß-PEA (Carlsson et al., 1972) . NSD 1015 pretreatment, at a dose that selectively blocks dopamine decarboxylase activity (30.0 mg/kg administered 30 min before (R)-(-)-deprenyl) (Lamensdorf and Finberg, 1997; Treseder et al., 2003) , significantly reduced the ability of (R)-(-)-deprenyl to generalize to the methamphetamine-discriminative stimulus in rats under the stimulus-shock termination schedule, but not under the food-reinforcement schedule.
NSD1015, also, partially reduced the ability of (R)-(-)-deprenyl to generalize to the cocainediscriminative stimulus under the stimulus-shock termination schedule. These results suggest that increased levels of ß-PEA after administration of large doses of (R)-(-)-deprenyl may play a facilitatory role in the psychostimulant-like discriminative effects of (R)-(-)-deprenyl. The limited ability of (R)-(-)-deprenyl to markedly depress MAO-B activity when given acutely may result in the need for very high doses of (R)-(-)-deprenyl in order to produce blockade of MAO-B activity rapidly enough to elevate ß-PEA levels within the one-hr time frame of measured effects (30-min (R)-(-)-deprenyl pretreatment followed by 30-min session) to levels sufficient to facilitate the psychostimulant-like discriminative effects of the (R)-(-)-methamphetamine and (R)-(-)-amphetamine metabolites.
In conclusion, the delayed appearance of psychostimulant-like discriminative effects of (R)-(-)-deprenyl, the failure to find psychostimulant-like discriminative effects with Ro 16-1649 and the reversal of (R)-(-)-deprenyl's psychostimulant-like discriminative effects by blockade of its metabolism with SKF 525A demonstrate that the psychostimulant-like discriminative effects of 
